FILE PHOTO: The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. REUTERS/Arnd Wiegmann
ZURICH (Reuters) -Contract drug manufacturer Lonza will double its production capacity in Switzerland for Moderna's COVID-19 vaccine, helping boost the U.S. drugmaker's output to as many as 3 billion doses in 2022. [L1N2ML2XZ]
The deal announced on Thursday extends a 10-year pact and foresees three further production lines in Visp, Switzerland, beyond the three Lonza built since last year.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
